Microorganisms for the production of 1,4-butanediol and related methods

US9434964B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9434964-B2
Application numberUS-201213361799-A
CountryUS
Kind codeB2
Filing dateJan 30, 2012
Priority dateJun 4, 2009
Publication dateSep 6, 2016
Grant dateSep 6, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO) pathway comprising at least one exogenous nucleic acid encoding a BDO pathway enzyme expressed in a sufficient amount to produce BDO and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO.

First claim

Opening claim text (preview).

What is claimed is: 1. A non-naturally occurring Escherichia coli , comprising a 1,4-butanediol (BDO) pathway comprising one or more heterologous polynucleotides encoding BDO pathway enzymes expressed in a sufficient amount to produce BDO, wherein said E. coli: (A) comprises a BDO pathway comprising: (a) alpha-ketoglutarate decarboxylase; or alpha-ketoglutarate dehydrogenase and CoA-dependent succinate semialdehyde dehydrogenase; or glutamate:succinate semialdehyde transaminase and glutamate decarboxylase; (b) 4-hydroxybutyrate dehydrogenase; (c) 4-hydroxybutyryl-CoA transferase; or 4-hydroxybutyrate kinase and phosphotrans-4-hydroxybutyrylase; and (d) 4-hydroxybutyryl-CoA reductase and 4-hydroxybutyraldehyde reductase; or aldehyde/alcohol dehydrogenase, said aldehyde/alcohol dehydrogenase converting 4-hydroxybutyryl-CoA to 1,4-butanediol; and (B) comprises disruption of a gene encoding a protein in an aerobic respiratory control regulatory system; or expresses an exogenous NADH insensitive citrate synthase. 2. The non-naturally occurring E. coli of claim 1 , wherein said E. coli comprises disruption of a gene encoding a protein in an aerobic respiratory control regulatory system. 3. The non-naturally occurring E. coli of claim 2 , wherein said gene encoding the protein in the aerobic respiratory control regulatory system is an arcA gene. 4. The non-naturally occurring E. coli of claim 1 , wherein said E. coli expresses an exogenous NADH insensitive citrate synthase. 5. The non-naturally occurring E. coli of claim 4 , wherein said NADH insensitive citrate synthase is encoded by a gltA gene or a mutant gltA gene encoding an R163L mutant NADH insensitive citrate synthase. 6. The non-naturally occurring E. coli of claim 1 , wherein said E. coli further expresses an exogenous phosphoenolpyruvate carboxykinase. 7. The non-naturally occurring E. coli of claim 1 , further comprising disruption of a gene encoding malate dehydrogenase. 8. The non-naturally occurring E. coli of claim 1 , wherein one or more of said one or more heterologous nucleotides encoding BDO pathway enzymes are integrated into the fimD locus of the E. coli. 9. The non-naturally occurring E. coli of claim 1 , wherein said E. coli further expresses an exogenous non-phosphotransferase sucrose uptake system. 10. The non-naturally occurring E. coli of claim 1 , wherein said E. coli further comprises disruption of endogenous lactate dehydrogenase, endogenous alcohol dehydrogenase, and endogenous pyruvate formate lyase. 11. The non-naturally occurring E. coli of claim 1 , wherein said E. coli further expresses an exogenous pyruvate dehydrogenase. 12. The non-naturally occurring E. coli of claim 11 , wherein one or more genes encoding pyruvate dehydrogenase subunits is under the control of a pyruvate formate lyase promoter. 13. The non-naturally occurring E. coli of claim 11 , wherein said exogenous pyruvate dehydrogenase is NADH insensitive. 14. The non-naturally occurring E. coli of claim 11 , wherein said exogenous pyruvate dehydrogenase is encoded by the Klebsiella pneumonia lpdA gene. 15. The non-naturally occurring E. coli of claim 1 , wherein said succinate semialdehyde dehydrogenase, 4-hydroxybutyrate dehydrogenase and 4-hydroxybutyryl-CoA/acetyl-CoA transferase are encoded by Porphyromonas gingivalis W83 genes. 16. The non-naturally occurring E. coli of claim 1 , wherein said 4-hydroxybutyryl-CoA reductase is encoded by the Clostridium beijerinckii ald gene. 17. The non-naturally occurring E. coli of claim 1 , wherein said E. coli further expresses an exogenous succinyl-CoA synthetase. 18. The non-naturally occurring E. coli of claim 17 , wherein said succinyl-CoA synthetase is encoded by the Escherichia coli sucCD genes. 19. The non-naturally occurring E. coli of claim 1 , wherein said alpha-ketoglutarate decarboxylase is encoded by the Mycobacterium bovis sucA gene. 20. The non-naturally occurring E. coli of claim 1 , wherein said 4-hydroxybutyrate kinase and said phosphotrans-4-hydroxybutyrylase are encoded by the Clostridium acetobutylicum buk1 and ptb genes. 21. The non-naturally occurring E. coli of claim 1 , wherein said 4-hydroxybutyryl-CoA reductase is encoded by the Clostridium beijerinckii ald gene. 22. The non-naturally occurring E. coli of claim 1 , wherein said 4-hydroxybutyraldehyde reductase is encoded by the Geobacillus thermoglucosidasius adh1 gene. 23. The non-naturally occurring E. coli of claim 6 , wherein said phosphoenolpyruvate carboxykinase is encoded by the Haemophilus influenza phosphoenolpyruvate carboxykinase gene.

Assignees

Inventors

Classifications

  • containing a five-membered hetero ring, e.g. griseofulvin {, vitamin C} · CPC title

  • Preparation of tetrahydrofuran · CPC title

  • in position 2, the oxygen atom being in its keto or unsubstituted enol form · CPC title

  • Nitrogen as only ring hetero atom · CPC title

  • with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9434964B2 cover?
The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO) pathway comprising at least one exogenous nucleic acid encoding a BDO pathway enzyme expressed in a sufficient amount to produce BDO and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO.
Who is the assignee on this patent?
Van Dien Stephen J, Burgard Anthony P, Haselbeck Robert, and 8 more
What technology area does this patent fall under?
Primary CPC classification C12N15/52. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).